Refine by
Epilepsy Articles & Analysis: Older
82 news found
The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare neurological conditions with a primary focus on epilepsy. Furthermore, a nutraceutical version of the formulation, Mentanine™, is scheduled for clinical studies to investigate its potential applications across various ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
Hunter Land has extensive experience in cannabinoid research and is a member of the International Cannabinoid Research Society, American Epilepsy Society, and the American Academy of Neurology About: Neeka Health Neeka Health is a next-generation digital health technology company based out of Charlottetown (Prince Edward Island), Canada with a research and development subsidiary ...
Vincent's Hospital in Melbourne, Australia. Refractory epilepsy, referred to as uncontrolled, intractable, or drug-resistant epilepsy, occurs when medications do not bring seizures under control. Epilepsy patients that are refractory to oral anti-epileptic drug treatment have significantly higher mortality, higher morbidity, higher economic ...
People with contraindications to laser treatment include: people with photosensitive diseases, epilepsy, severe mental disorders, local skin inflammation, and pregnant women (hair removal treatment itself has no effect on the fetus, but the pain of hair removal may cause uterine contractions, so it is not recommended laser hair removal during pregnancy) and other people above ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD," including addiction. ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder “PTSD,” including addiction.The Company is the industry partner for research and product development with Dr. ...
The Beacon Platform is currently being used across therapeutic areas such as neurodegenerative disorders, epilepsy, sleep disorders and mental illness. "Our study represents an important advance for medical and life sciences research in Alzheimer's disease," said Jacob Donoghue, MD, PhD, co-founder and chief executive officer of Beacon Biosignals. ...
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. ...
(J Neuroscience 42:264–27, 2022) Epilepsy analysis Hashimoto et al. investigated the coupling between low- frequency and high-frequency activities (HFA) during tonic-clonic seizures in a retrospective study. ...
Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. Synchron is headquartered in New York City, with R&D facilities in Melbourne, ...
Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. Synchron is headquartered in New York City, with offices in Silicon Valley, California and R&D facilities in Melbourne, ...
The letter recaps the key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond directed at developing the Evo® platform thin film electrode technology for patients suffering from epilepsy, chronic back pain, and Parkinson's disease. In his letter, Dave Rosa, Chief Executive Officer of NeuroOne, states, "As we continue to develop ...
“Using this first-ever combined computational/data capability, pharmaceutical partners will be able to more efficiently and effectively develop new drugs to treat illnesses like depression, anxiety, bipolar disorder, Alzheimer’s, Parkinson’s, schizophrenia, epilepsy, anorexia, ADHD and PTSD.” With this partnership, the BIOiSIM platform will utilize its ...
“About a third of individuals with epilepsy have drug-resistant seizures. Removal or ablation of the affected temporal lobe can be an option, but many people with epilepsy are not eligible or interested in a tissue-destructive procedure. ...
SAIL data has been used widely in a range of research studies focusing on health and wellbeing, including COVID-19 vaccines/treatments, the impact of air pollution, dementia, epilepsy, cystic fibrosis and asthma. It can be used to study groups of people with particular characteristics or conditions, such as pregnant women or people over the age of 70 living with dementia, ...
Future applications may include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension, as well as non-medical solutions. ...
Inbrija further strengthens Biopas’ complete and innovative CNS portfolio now consisting of nine original treatments: for Parkinson’s disease, epilepsy, movement disorders, sialorrea, multiple sclerosis, anxiety, and sleep disorders,” said Pascal Forget, CEO of Biopas. ...